Intriguingly CP patients who consume excess alcohol have more peripheral blood Th1 cells. Alcohol increases gut permeability causing high circulating levels of lipopolysaccharide which is known to generate Th1 cell responses. These combined features may contribute to the pathogenesis of CP.

Competing interests None declared.

REFERENCES

OC-112

UTILITIY OF CYST FLUID AMYLASE IN THE DIFFERENTIATION OF SUSPECTED PANCREATIC NEOCYSTS

doi:10.1136/gutjnl-2012-302514a.112

1K Oppong, 2K Binar, 3J Leeds, 4M Dawwas, 5M K Nayyar. 1HPB Unit, Freeman Hospital, Newcastle upon Tyne, UK; 2Department of Gastroenterology, Torbay District general Hospital, Torquay, UK; 3Department of Gastroenterology, Aberdeen Royal Infirmary, Aberdeen, UK

Introduction The Differentiation of mucinous (mCA, IPMN) from non-mucinous pancreatic cysts is important because of the malignant potential of the former. Cyst fluid amylase is known to be elevated in cysts with overt communication with the pancreatic duct (Pseudocysts and IPMN) recent data has also suggested it may be elevated in mCA and that malignant mucinous cysts have a significantly lower level than benign. We aimed to assess the diagnostic performance of cyst fluid amylase in a large cohort of histologically confirmed pancreatic cysts.

Methods The study population comprised all patients with suspected neoplastic pancreatic cysts who underwent EUS-FNA between June 2003 and October 2011. The study group consisted of all patients with a definitive diagnosis (ressection histology, biopsy histology or malignant cytology) in whom a cyst amylase value had been recorded. Test performance was compared using Mann–Whitney U test and an ROC curve was generated to characterise the diagnostic performance of cyst fluid amylase to differentiate pseudocyst from non pseudocyst.

Results During the study period 334 cyst EUS-FNA procedures were performed. A definitive diagnosis was available for 93 individuals, an amylase level was available for 59/93 (63.4%) of cases. 57 mucinous cyst (24 benign, 13 malignant), 22 non-mucinous (eight pseudocysts). Median values (IU/L) and IQR for differing categories of cyst fluid amylase was available for 59/93 (63.4%) of cases. 37 mucinous cyst (24 benign, 13 malignant), 22 non-mucinous (eight pseudocysts). Median values (IU/L) and IQR for differing categories of cyst fluid amylase in histologically confirmed pancreatic cysts. The diagnostic performance of cyst fluid amylase was investigated.

Conclusion Cyst fluid amylase while significantly elevated in pseudocysts cannot be solely relied upon to distinguish from mucinous cysts and cannot be used to differentiate between IPMN and mCA.

Competing interests None declared.

OC-113

PREVENTION OF POST-ERCP ACUTE PANCREATITIS: COMPLETE SYSTEMATIC REVIEW

doi:10.1136/gutjnl-2012-302514a.113

1K Atal, 2M A Javed, 3D Lythgoe, 4W Wright, 5R Sutton, 6Department of Molecular and Clinical cancer medicine, Liverpool NIHR Pancreas Biomedical Research Unit, Liverpool, UK; 2Department of Medical statistics, University of Liverpool, Liverpool, UK

Introduction Post-ERCP acute pancreatitis (post-ERCP-AP) occurs in ~5% of patients undergoing ERCP; severe in ~1%. Despite multiple trials, optimal prophylaxis remains undetermined. We sought to clarify the effectiveness of prophylactic interventions for post-ERCP AP through multiple meta-analyses of randomised controlled trials (RCTs).

Methods MEDLINE, EMBASE and the Cochrane Library were searched by two independent reviewers to identify all RCTs that tested treatments to reduce post-ERCP AP. Data were extracted to permit Jadad scoring, grouping of RCTs by therapeutic mechanism and separate meta-analysis of each group. The main outcome measure was post-ERCP AP defined as amylase elevated to >3x upper limit of normal with >24h abdominal pain.

Results 71 RCTs of the highest quality (Jadad score 5 for pharmaceutical and three for interventional trials) were identified. Pancreatic stents (trials (T)—5; patients (P)—577; RR 0.20, 95% CI 0.09 to 0.42) were most effective; significant reductions in post-ERCP AP resulted from secretion inhibitors (T—12; P—4581; RR 0.54; CI 0.36 to 0.83), protease inhibitors (T—9; P—5752; RR 0.54; CI 0.38 to 0.78) and smooth muscle relaxants (T—9; P—2110; RR 0.67; CI 0.52 to 0.87). Non-steroidal anti-inflammatory drugs (NSAIDs; T—4; P—753; RR 0.68; CI 0.46 to 1.00), interleukin-10 (IL-10; T—3; P—642; RR 0.79; CI 0.55 to 1.14), anti-oxidants (T—5; P—2100; RR 0.90; CI 0.54 to 1.50), anti-coagulants (T—2; P—533; RR 0.85; CI 0.48 to 1.53), non-ionic (vs contrast agents (T—9; P—3059; RR 1.52; CI 0.92 to 2.48), wire guided cannulation (T—7; P—2168; RR 0.65; CI 0.34 to 1.17) pre cut papillotomy (T—4; P—558; RR 0.57; CI 0.20 to 1.59) and steroids (T—3; P—924; RR 1.09; CI 0.70 to 1.70) did not reduce post-ERCP AP.

Conclusion This is the most comprehensive systematic review on the subject to date which shows that pancreatic stents, secretion and protease inhibitors and smooth muscle relaxants reduce the risk of post-ERCP AP. Large well-designed RCTs of combination vs single agent prophylaxis are required.

Competing interests None declared.

Colorectal free papers

OC-114

EMR VS ESD FOR THE RESECTION OF LARGE RECTOSIGMOID LESIONS: DATA FROM A LARGE UK CENTRE

doi:10.1136/gutjnl-2012-302514a.114

G Longcroft-Wheaton,* P Bhandari. Department of Gastroenterology, Portsmouth Hospitals NHS Trust, Portsmouth, UK

Introduction Endoscopic resection of large benign rectal lesions is becoming established as an attractive alternative to surgery. However, the optimal technique is not clear. This series compares the experience of EMR and ESD in a tertiary referral centre.
Methods A prospective review of patients undergoing endoscopic resection of neoplastic polyps in the rectosigmoid colon. Patients were tertiary referrals from experienced consultants. The polyps were considered technically challenging due to size, difficult lesion access or recurrences on previous EMR scars. Referral was made prior to surgical referral. All lesions were assessed using indigo-carmine chromoendoscopy and lesions suspicious for invasive malignancy were excluded. The choice of endoscopic technique was made based on the Endoscopist’s judgement of best approach for each lesion. Completeness of resection was recorded. Endoscopic follow-up was performed to assess for incomplete resection or recurrence.

Results 45 lesions were resected by ESD technique and 100 by EMR technique. For ESD procedures the median lesion size was 40 mm (range 20–150), 19/45 were salvage procedures post failed attempts at endoscopic resection. Endoscopic clearance was achieved at first attempt in 91% of the procedures. A further 7% were cleared in a subsequent procedure. One patient was referred for surgery for perforation and two patients went to surgery for unsuspected cancer found on histological examination of the resection specimen. At endoscopic follow-up 100% had complete clearance with no residual disease. There was one perforation requiring surgery, two microperforations (endoscopically managed), three delayed bleeds and two post polypectomy syndromes (conservatively managed) giving an overall complication rate of 18%. For the EMR cohort the median lesion size was 40 mm (range 20–100). All procedures were primary resections. Endoscopic clearance was achieved in 90% of cases. Two patients were referred for surgery for incomplete resection. In seven patients unsuspected cancer was found, all of whom were referred for surgery. At endoscopic follow-up 95% of cases had achieved complete clearance with no residual disease. There was seven delayed bleeds and one post polypectomy syndrome giving an overall complication rate of 8%.

Conclusion Both EMR and ESD results in an excellent complete clearance rate. While ESD appears to result in fewer recurrences at follow-up it is associated with an increased complication rate compared to EMR, predominately due to the risk of perforation. However, it is effective in patients with previous failed attempts at resection. It should be considered as an option for difficult or scarred lesions where complete clearance with EMR could be difficult.

Competing interests None declared.

OC-115 COMPARISON OF SCREEN DETECTED AND INTERVAL COLORECTAL CANCERS IN THE BOWEL CANCER SCREENING PROGRAMME: EXPERIENCE FROM THE NORTH EAST OF ENGLAND

doi:10.1136/gutjnl-2012-302514a.115

1,2,3M Gill,* 2,3,M G Bramble, 2,3 C J Rees, 1,3 M Bradburn, 3,J T J Lee, 1,3 S J Mills. 1,3Northern Colorectal Cancer Audit Group, Northern England; 2University of Durham, Durham, UK; 3Northern Region Endoscopy Group, Northern England; 4University of Newcastle, Newcastle, UK

Introduction The NHS Bowel Cancer Screening Programme (BCSP) commenced screening in North East England in February 2007. It offers biennial faecal occult blood testing (FOBT) followed by colonoscopy for those with a positive FOBT. All cases of colorectal cancer (CRC) known to the MDTs in this region are registered with the Northern Colorectal Cancer Audit Group (NORCCAG) database.

Methods CRCs occurring in the screening population (aged 60–69 years) between April 2007 and March 2010 were identified from the NORCCAG database. Their screening history was obtained by cross-referencing this database with the regional BCSP database. Cases were classified into four groups: a control group (cancers diagnosed prior to first screening invite), screen detected, interval (cancers diagnosed between screening rounds after a negative FOBT) and non-uptake (patients who declined screening). Patient demographics, tumour characteristics and survival were compared between the four groups.

Results 1336 CRCs were diagnosed in the screening population. 511 (38.2%) cancers were in the control group. 825 cancers (61.8%) were detected in individuals who had been invited for screening. 522 (39.0%) were screen detected, 511 (37.7%) were in the non-uptake group and 192 (23.3%) were interval cancers. All of the interval cancers followed a negative FOBT. Compared to both the control group and the interval cancer group, the proportion of males in the screen detected group was significantly higher (73.0% vs 62.4% & 60.4%, χ²=9.38, p=0.002 and χ²=8.77, p=0.003 respectively). Screen detected cancers were more likely to be left sided than in the control or interval cancer groups (78.6% vs 70.1% & 66.7%, χ²=7.52, p=0.007 & χ²=8.89, p=0.005). Significantly more Dukes A and fewer Dukes D cancers were found in the screen detected group compared to the control and interval groups (p<0.05). Screen detected cancers had a superior survival compared to interval cancers (χ²=50.86, p<0.001) and the control group (χ²=53.62, p<0.001). There was no difference in patient demographics, tumour location, stage of tumour nor survival between control and interval cancer groups.

Conclusion This is one of the first studies that provides data on the performance of the BCSP in one region since its national implementation. The FOBT test is better at detecting cancers in the left colon and in men. There are significant numbers of interval cancers, which were not found to have an improved outcome compared to the non-screened population as has previously been published.

Competing interests None declared.

OC-116 BOWEL SCREENING WALES—FIRST ROUND REPORT
doi:10.1136/gutjnl-2012-302514a.116

H Heard,* Bowel Screening Wales, Llantrisant, UK

Introduction This report describes the first round of Bowel Screening Wales (BSW). It is the first overview showing the entire performance of the national bowel screening programme in Wales.

Methods The first round for BSW took place between 27 October 2008 and 24 November 2010. The Bowel Screening Information Management System obtains demographic information directly from the Welsh Demographic Service (WDS). This is the basis for the activity and outcome data presented here. This report is based on information available to BSW on the 1 August 2011.

Results A total of 847,773 invitation letters were issued to 412,025 participants. 55.2% of participants invited returned a completed test kit within six months of invitation date. Women have a higher uptake (53.8%) compared to men (51.5%). Uptake around Wales varies between areas, ranging from 49% in Wrexham and Cardiff to nearly 59% in Anglesey and Bridgend. Initially, positive rates were as expected at around 0.2% for Faecal Occult Blood (FOB) kits, rising to 0.5%. Positive rates for both test kits were 2.5% and 2.4% in early 2009, rising to 3% during 2009. Around 1% of Faecal Immunochemical Test (FIT) kits were spilt compared to 1.8% of FOB test kits. 6807 participants with a positive test result made an appointment to see a healthcare professional. The majority were by phone with only seven participants attending face to face. 5594 participants were found fit for colonoscopy and offered the procedure. 89.4% of these attended with 2.8% declining and 0.2% not attending. Waiting times for colonoscopy were on average around 10 weeks. Abstract OC-116 table 1 shows the final outcome of the 5230 colonoscopy procedures.